Angiogenesis and antiangiogenic approaches to sarcomas.
Established chemotherapy regimens for advanced or metastatic sarcoma generally have low response rates and substantial toxicity, and resistance often arises quickly, making sarcoma an ideal target for alternative treatment approaches. Antiangiogenic therapies have a number of potential advantages including decreased resistance, fewer side effects, and a broad spectrum of activity. This paper reviews the evidence supporting the use of antiangiogenic therapies for adult soft tissue sarcomas. Human sarcomas express a number of proangiogenic factors that may represent therapeutic targets, with vascular endothelial growth factor being the best characterized, and inhibitors of angiogenesis have antitumor activity in animal models of human sarcomas. Clinical trials are in early stages, although promising results have already been seen. In the future, improved drugs, refined molecular profiling of tumors, and new ways of combining antiangiogenic agents with cytotoxic agents may lead to more effective and tolerable therapies for sarcomas.
Heymach
J V
JV
Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. jheymach@partners.org
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D005544:Forecasting; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D012509:Sarcoma / Q000098:blood supply* / Q000628:therapy; D012983:Soft Tissue Neoplasms / Q000098:blood supply* / Q000188:drug therapy
D020533:Angiogenesis Inhibitors